

Helsinki, 09 September 2021

Addressees

Registrant(s) of JS_36609-29-7 as listed in the last Appendix of this decision

Date of submission of the dossier subject to this decision

13 September 2018

Registered substance subject to this decision ("the Substance")

Substance name: 2-Oxepanone, polymer with 1,6-hexanediol

EC number: 609-271-5

CAS number: 36609-29-7

Decision number: Please refer to the REACH-IT message which delivered this communication (in format CCH-D-XXXXXXXXXX-XX-XX/F)**DECISION TAKEN UNDER ARTICLE 42(1) OF THE REACH REGULATION**

By the above-mentioned decision of 13 April 2016 ("the original decision") ECHA requested you to submit information by 20 April 2018 in an update of your registration dossier.

Based on Article 42(1) of Regulation (EC) No 1907/2006 (the 'REACH Regulation'), ECHA examined the information you submitted with the registration update specified in the header above, and concludes that

Your registration still does not comply with the following information requirement(s):**A. Information required from all the Registrants subject to Annex IX of REACH****Pre-natal developmental toxicity study (OECD 414) in rats, using the analogue substance 2-oxepanone, polymer with 1,4-butanediol (EC no 608-670-1).**

You are therefore still required to provide this information requested in the original decision.

Reasons for the request(s) are explained in the following appendix:

- Appendix entitled "Reasons to request information required under Annexes VII to X of REACH", respectively.

Appeal

This decision, when adopted under Article 51 of REACH, may be appealed to the Board of Appeal of ECHA within three months of its notification to you. Please refer to <http://echa.europa.eu/regulations/appeals> for further information.

Failure to comply

The respective Member State competent authority (MSCA) and National enforcement authority (NEA) will be informed of this decision. They may consider enforcement actions to secure the implementation of the original decision and exercise the powers reserved to them

under Article 126 of Regulation No 1907/2006 (penalties for non-compliance)¹.

Authorised² under the authority of Christel Schilliger-Musset, Director of Hazard Assessment

¹ See paragraphs 61 and 114 of the judgment of 8 May of the General Court of the European Court of Justice in Case T-283/15 Esso Raffinage v. ECHA

² As this is an electronic document, it is not physically signed. This communication has been approved according to ECHA's internal decision-approval process.

Appendix A: Reasons to request information required under Annex IX of REACH**Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.) in a first species**

You were requested to submit information derived with the analogue substance 2-oxepanone, polymer with 1,4-butanediol (EC no 608-670-1) for pre-natal developmental toxicity study.

In response, you provided: a GLP-compliant prenatal developmental toxicity study according to the EU B.31/OECD TG 414 via an oral route in rats with the registered substance. You have attached some tables as a PDF file, with a watermark "[REDACTED]".

We have assessed this information and identified the following issue(s):

In order to be considered compliant and enable assessing if the Substance is a developmental toxicant, the study has to meet the requirements of OECD TG 414. The information required to demonstrate compliance with this test guideline include e.g.

- Final report date
- Number of pregnant and non-pregnant dams
- Number of dams with abortions, early deliveries, stillbirths, resorptions, and/or dead fetuses
- Pre-and post-implantation loss, number and percent
- Body weight, body weight change and gravid uterine weight, including optionally, body weight change corrected for gravid uterine weight
- Mean number and percent of live offspring
- Mean foetal/pup body weight by sex and sexes combined
- Number and percent of fetuses and litters with malformation (including runts) and/or variation as well as description and incidences of malformations and main variations (and/or retardation).
- Historical control data if used to argue about adversity of effects
- Provide data preferably in **tabular form** where applicable

In the updated registration subject to follow-up evaluation, you have not provided the information listed above.

Based on the above, the information you provided does not fulfil the information requirement and you are still required to provide the Pre-natal developmental toxicity study (Annex IX, Section 8.7.2.; test method: EUB.31/OECD 414) in rats, oral route.

Appendix B: Requirements to fulfil when conducting and reporting new tests for REACH purposes

A. Test methods, GLP requirements and reporting

1. Under Article 13(3) of REACH, all new data generated as a result of this decision must be conducted according to the test methods laid down in a European Commission Regulation or to international test methods recognised by the Commission or ECHA as being appropriate.
2. Under Article 13(4) of REACH, ecotoxicological and toxicological tests and analyses must be carried out according to the GLP principles (Directive 2004/10/EC) or other international standards recognised by the Commission or ECHA.
3. Under Article 10(a)(vi) and (vii) of REACH, all new data generated as a result of this decision must be reported as study summaries, or as robust study summaries, if required under Annex I of REACH. See ECHA Practical Guide on How to report robust study summaries³.

³ <https://echa.europa.eu/practical-guides>

Appendix C: Procedure

In accordance with Article 42(1) of the REACH Regulation, the Agency examined the information submitted by you in consequence of decision of 13 April 2016 ("the original decision"). Agency considered that this information did not meet one or more of the requests contained in that decision. ECHA contacted you informally in two occasions (firstly with a letter on 30 August 2018, TPE-C-2114442295-50-01/F and then with a message to your REACH-IT account on 21 September 2018), and invited you to provide the missing information outlined in Appendix A. ECHA recommended also that you include the final study report and the date of the final report.

You did not respond to any of our communication. Therefore, a new decision-making process was initiated under Article 40 of the REACH Regulation.

This decision does not prevent ECHA from initiating further compliance checks at a later stage on the registrations present.

ECHA followed the procedure detailed in Articles 50 and 51 of REACH.

ECHA notified you of the draft decision and invited you to provide comments.

ECHA did not receive any comments within the commenting period.

ECHA notified the draft decision to the competent authorities of the Member States for proposals for amendment.

As no amendments were proposed, ECHA adopted the decision under Article 51(3) of REACH.

Appendix D: List of references - ECHA Guidance⁴ and other supporting documents

Evaluation of available information

Guidance on information requirements and chemical safety assessment, Chapter R.4 (version 1.1., December 2011), referred to as ECHA Guidance R.4 where relevant.

QSARs, read-across and grouping

Guidance on information requirements and chemical safety assessment, Chapter R.6 (version 1.0, May 2008), referred to as ECHA Guidance R.6 where relevant.

Read-across assessment framework (RAAF, March 2017)⁵

RAAF - considerations on multiconstituent substances and UVCBs (RAAF UVCB, March 2017)⁵

Physical-chemical properties

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Toxicology

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

Environmental toxicology and fate

Guidance on information requirements and chemical safety assessment, Chapter R.7a (version 6.0, July 2017), referred to as ECHA Guidance R.7a in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7b (version 4.0, June 2017), referred to as ECHA Guidance R.7b in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.7c (version 3.0, June 2017), referred to as ECHA Guidance R.7c in this decision.

PBT assessment

Guidance on information requirements and chemical safety assessment, Chapter R.11 (version 3.0, June 2017), referred to as ECHA Guidance R.11 in this decision.

Guidance on information requirements and chemical safety assessment, Chapter R.16 (version 3.0, February 2016), referred to as ECHA Guidance R.16 in this decision.

Data sharing

Guidance on data-sharing (version 3.1, January 2017), referred to as ECHA Guidance on data sharing in this decision.

OECD Guidance documents⁶

⁴ <https://echa.europa.eu/guidance-documents/guidance-on-information-requirements-and-chemical-safety-assessment>

⁵ <https://echa.europa.eu/support/registration/how-to-avoid-unnecessary-testing-on-animals/grouping-of-substances-and-read-across>

⁶ <http://www.oecd.org/chemicalsafety/testing/series-testing-assessment-publications-number.htm>

Guidance Document on aqueous-phase aquatic toxicity testing of difficult test chemicals – No 23, referred to as OECD GD 23.

Guidance document on transformation/dissolution of metals and metal compounds in aqueous media – No 29, referred to as OECD GD 29.

Guidance Document on Standardised Test Guidelines for Evaluating Chemicals for Endocrine Disruption – No 150, referred to as OECD GD 150.

Guidance Document supporting OECD test guideline 443 on the extended one-generation reproductive toxicity test – No 151, referred to as OECD GD 151.

Appendix E: Addressees of this decision and the corresponding information requirements applicable to them

You must provide the information requested in this decision for all REACH Annexes applicable to you.

Registrant Name	Registration number	Highest REACH Annex applicable to you
████████████████████	████████████████	████

Where applicable, the name of a third party representative (TPR) may be displayed in the list of recipients whereas ECHA will send the decision to the actual registrant.